| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Catheter Precision, Inc.$0.79
-0.33 (-28.95%)
F 2Pipeline Score MedTech · Pre-Clinical
Market Cap
2.28 M
EPS
-13.69
P/E Ratio
-
Value Trade
47.19 K
SEC Financials
Q1 2026Dilution Risk
Revenue
432.00 K
R&D Expenses
149.00 K
Operating CF
-2.80 M
Total Assets
35.09 M
Total Liabilities
25.93 M
Equity
9.57 M
D/E Ratio
12,345
1.8 %
Week
-10.74 %
1 Month
-47 %
3 Month
-44.54 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
441.00 K
Monthly Burn
932.00 K
Runway
0 mo
Burn Trend
SEC Filing
May 18, 2026
Overview
Volume
2.45 M
52 Week Range
0.75 - 15.68
% held by Insiders
26.87 %
% held by Institutions
3.78 %
Enterprise Value
14.23 M
Total Shares
2.36 M
Short %
15.6 %
Float Shares
1.86 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 3%
Micro Cap (rank 885 of 911)
Percentile RankCatheter Precision, Inc. has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VIVO | ventricular tachycardia | — | 2026-04-23 | This study included 31 patients and mapped 48 VTs with VIVO and standard of care electroanatomical mapping systems to determine accuracy. Read More | Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting Read More | |
VIVO | ventricular tachycardia | — | 2026-04-23 | This study included 31 patients and mapped 48 VTs with VIVO and standard of care electroanatomical mapping systems to determine accuracy. Read More | Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting Read More | |
VIVO | ventricular tachycardia | — | 2026-04-23 | This study included 31 patients and mapped 48 VTs with VIVO and standard of care electroanatomical mapping systems to determine accuracy. Read More | Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VTAK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VTAK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VTAKCatheter Precision, Inc. Announces Issuance of Two Key Patents
Catheter Precision, Inc. has announced the issuance of two significant patents aimed at improving cardiac electrophysiology treatments. The first patent focuses on precise localization of cardiac arrhythmias using internal electrocardiography signals, while the second pertains to denoising physiological signals during electrical neuromodulation for heart failure. The company is optimistic about the potential of these technologies in addressing unmet medical needs.
Read more →VTAKCatheter Precision, Inc. Announces Allowance of Key Intellectual Property
Catheter Precision, Inc. has announced the allowance of several new patents related to its heart failure and vascular closure technologies. The company received eight patents, including six for heart failure and three for vascular closure, which bolster its intellectual property portfolio. CEO David Jenkins expressed optimism about these developments, especially as they relate to ongoing discussions for potential technology sales.
Read more →VTAK▲ +9.1%on this news
CATHETER PRECISION REPORTS 200% REVENUE GROWTH AND COMPLETES TRANSFORMATIVE FLYTE ACQUISITION
Catheter Precision, Inc. reported a remarkable 200% revenue growth in Q1 2026, reaching $432,000. The company successfully acquired Flyte, enhancing its aviation platform and generating immediate revenue. Additionally, the medical device segment showed strong global expansion, with products now utilized in 15 countries. The net loss significantly decreased, indicating improved financial performance.
Read more →VTAKFlyte Increases Capacity and Launches Hiring Initiative as Spirit Airlines Shutdown Disrupts U.S. Air Travel
Flyte, a regional air mobility subsidiary of Catheter Precision, is increasing its flight capacity and launching a hiring initiative in response to the shutdown of Spirit Airlines. This disruption has led to widespread cancellations and impacted thousands of employees. Flyte aims to provide opportunities for affected aviation professionals while expanding its fleet and regional service offerings.
Read more →VTAKCatheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting
Catheter Precision, Inc. (VTAK) announced its attendance at the 47th Annual Heart Rhythm Society Meeting, where it will present new clinical data on its VIVO system. The conference, which highlights advancements in electrophysiology, will showcase an abstract on the feasibility of using intra-cardiac electrodes for diagnosing ventricular tachycardia. Additionally, the meeting will feature presentations on the integration of recorded data for improved arrhythmia localization. The recent acceptance of their studies in leading journals further supports the company's innovative contributions to arrhythmia care.
Read more →VTAKCatheter Precision Secures U.S. Patent Allowance on Foundational Surgical Technology, Establishing Powerful IP and Accelerating Scalable Growth Strategy
Catheter Precision, Inc. (VTAK) has received a Notice of Allowance from the USPTO for its proprietary surgical vessel closing pressure device, marking a key milestone in its intellectual property strategy. The allowed claims cover both the device's architecture and its method of use, establishing significant barriers to entry in the medical technology market. CEO David A. Jenkins emphasized that this achievement supports their growth strategy and long-term shareholder value. The patent is expected to play a crucial role in the company's product development and commercialization efforts.
Read more →VTAKCatheter Precision Announces Accepted Publication in Leading European Medical Journal
Catheter Precision, Inc. announced that its VIVO study results have been accepted for publication in EP Europace. The study demonstrated that VIVO can accurately predict arrhythmogenic substrates in patients with scar-dependent ventricular tachycardia. CEO David Jenkins highlighted the potential of VIVO to improve procedural workflows and reduce procedure times. A larger multi-center study is planned to further validate these findings.
Read more →VTAKCatheter Precision to Attend the Annual European Heart Rhythm Association Conference
Catheter Precision, Inc. (VTAK) has announced its participation in the Annual European Heart Rhythm Association Conference in Paris scheduled for April 12-14, 2026. This marks the company's first major European conference appearance after receiving CE Mark approval for its product LockeT, which assists in wound closure following venous punctures. CEO David Jenkins emphasized the importance of conferences for sharing updates and connecting with key professionals in the field. The event will also highlight other innovations, including the VIVO imaging system designed to streamline procedures for arrhythmias.
Read more →VTAKCatheter Precision Engages Strategic Advisor
Catheter Precision, Inc. (NYSE American: VTAK) has appointed a strategic advisor to facilitate the sale of its cardiac electrophysiology business, aiming to enhance shareholder value and focus on its aviation platform. CEO David Jenkins believes that the company's current market capitalization does not fully reflect the value of its cardiac assets, which have received significant FDA and CE approvals. By monetizing these assets, the company aims to position itself as a dedicated player in the aviation sector. The strategic move reflects a calculated effort to drive shareholder value through focused growth.
Read more →VTAKCatheter Precision Reports 2025 Results and Updates on Strategic Expansion
Catheter Precision, Inc. (VTAK) reported significant operational achievements and financial growth for 2025, with a 95% year-over-year revenue increase. Key milestones include receiving CE Mark for the LockeT device and expanding the customer base with 32 new clients. The company also acquired Flyte, a regional air mobility firm, indicating a strategic diversification into aviation. However, net losses increased slightly during the year, highlighting ongoing financial challenges despite revenue growth.
Read more →VTAKFlyte Hops: Vision Jet Platform Seeks to Redefine Private Aviation
Flyte, a subsidiary of Catheter Precision, is expanding its Vision Jet-powered Hops platform aimed at redefining private aviation. The platform focuses on short-haul regional travel, emphasizing safety, speed, and affordability. With plans to add two more jets by Memorial Day 2026, Flyte aims to transform private aviation into a practical transportation solution. The Vision Jet features advanced safety technologies, including a full-aircraft parachute system and autonomous landing capabilities.
Read more →VTAK▼ -7%on this news· ran to -18% by day 3
Catheter Precision, Inc. Secures up to $88 Million in Strategic Institutional Financing Commitments to Fund Accelerated Growth
Catheter Precision, Inc. (VTAK) has secured up to $88 million in strategic financing to enhance its growth initiatives, particularly through its recently acquired subsidiary, Fly Flyte, Inc. The funds will support fleet expansion, market entry, and infrastructure scaling. VTAK is positioned to capitalize on the increasing demand for premium regional air mobility services, leveraging its fully operational aviation platform and strong balance sheet enhancements. Management believes this will significantly streamline operations and create a focused high-growth strategy in a burgeoning market.
Read more →VTAKCatheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026
Catheter Precision, Inc. announced that its LockeT suture retention device will be showcased during live cases at the International Symposium of Left Atrial Appendage 2026. This event will feature hands-on demonstrations that allow electrophysiology fellows to interact with the device and ask questions. The company emphasizes the cost-saving benefits of its product, such as reduced hospital costs and same-day discharge for patients. CEO David Jenkins highlighted the importance of live clinical cases in validating the device's effectiveness. While the outlook for LockeT is positive, the company acknowledges potential risks associated with forward-looking statements.
Read more →VTAK▼ -6.5%on this news
Catheter Precision Announces Strategic Sale of Non-Core Assets to Strengthen Balance Sheet and Accelerate Electrophysiology Growth
Catheter Precision, Inc. (NYSE American: VTAK) has entered a definitive agreement to sell its atherectomy catheter technologies to streamline its operations and enhance its focus on the electrophysiology sector. The transaction includes an upfront cash payment of $15,000, an equity stake in the acquiring company, and a ten-year royalty agreement tied to net sales. This move aims to strengthen Catheter Precision's balance sheet and accelerate growth within its core cardiac arrhythmia technologies. The company believes these changes will position it favorably for future commercial endeavors.
Read more →VTAK▲ +11.9%on this newsshared move
VTAK Acquires 19.98% Strategic Stake in AI-Enabled Aviation Company Fly Flyte, Inc.
Catheter Precision, Inc. (VTAK) has acquired a 19.98% stake in Fly Flyte, Inc., an FAA-certified aviation operator. This strategic investment allows VTAK to tap into a revenue-generating business that utilizes AI technology and operates a fleet of Cirrus Vision Jets. The partnership aims to enhance capital allocation into the growing regional air mobility sector, positioning both companies for future growth.
Read more →VTAK▼ -33.2%on this newsshared move
Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth
Catheter Precision, Inc. has terminated its at-the-market equity offering program and secured up to $36.5 million in strategic financing from institutional investors. This move is aimed at accelerating the company's growth and strengthening its financial position. CEO David Jenkins emphasized the importance of this financing in enhancing investor confidence and enabling disciplined growth.
Read more →VTAKCatheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at Scripps’ Structural Heart Intervention and Imaging 2026 Conference
Catheter Precision's LockeT suture retention device will be featured in live cases at the Scripps Structural Heart Intervention and Imaging 2026 Conference. The event, taking place from February 11-13, 2026, will highlight the device's role in improving workflow efficiency and patient recovery. CEO David Jenkins expressed pride in showcasing LockeT at this significant clinical gathering.
Read more →VTAKCatheter Precision Announces Accelerated Momentum for LockeT Device with New Hospital Approvals and Strong Q1 Adoption Outlook
Catheter Precision, Inc. has reported significant progress in the adoption of its LockeT suture retention device, with increased hospital evaluations and approvals. The company has achieved its highest revenue in January and is expanding into international markets. Positive feedback from hospitals indicates that LockeT meets critical needs in wound closure, supporting expectations for strong adoption in the first quarter of 2026.
Read more →VTAK▲ +10.4%on this news
Catheter Precision Receives First Purchase Order for LockeT in Germany
Catheter Precision, Inc. (VTAK) has received its first purchase order for the LockeT suture retention device from Universitätsklinikum Frankfurt in Germany. This order signifies the company's entry into the German market, which is the largest healthcare sector in Europe. The LockeT device aims to improve workflow efficiency after venous catheter access and is viewed as a crucial step in Catheter Precision's growth strategy in the region. The company highlights the clinical value of its technology through this partnership, positioning itself for further expansion across Europe.
Read more →VTAKCatheter Precision Received new VIVO Purchase Order from Leading Hospital in Slovenia
Catheter Precision, Inc. (VTAK) announced a new VIVO purchase order from University Clinical Center Ljubljana in Slovenia, expanding its sales to 15 countries. This achievement reflects the company’s growth and the acceptance of its products, including the non-invasive VIVO imaging system and the LockeT wound closure device. The CEO emphasized the significance of this expansion in the context of solving real-world challenges in electrophysiology lab workflows. This follows a year of robust growth and plans for continued commercial expansion in 2026.
Read more →VTAKCatheter Precision (VTAK) Announces Expansion of LockeT into an Eighth European Country Since Receipt of CE Mark
Catheter Precision, Inc. (VTAK) has expanded its LockeT device into Ireland with a successful implementation at Mater Private Hospital in Dublin. This marks a significant step in the company's global growth strategy, with LockeT now being recognized for enhancing the safety and efficiency of cardiac procedures. The device's intuitive design facilitated swift training of hospital staff, demonstrating its operational effectiveness. This partnership further establishes Catheter Precision's commitment to advancing electrophysiology solutions in international markets.
Read more →VTAK▲ +13.3%on this news· ran to +40% by day 3
Catheter Precision Secures Tender From Leading Hospital in Hungary
Catheter Precision, Inc. announced the successful securing of a significant tender at Albert Szent-Györgyi Health Centre in Hungary for its VIVO system. This achievement marks the company’s first installation in Hungary and is a step forward in its growth strategy in Central and Eastern Europe. The installation is expected in the first quarter of 2026 and underscores the clinical value of the VIVO system, which offers non-invasive 3D localization of ventricular tachycardia. Catheter Precision continues to expand its global footprint and improve patient outcomes with its innovative technologies.
Read more →VTAKCatheter Precision Announces Launch of LockeT in Switzerland
Catheter Precision, Inc. (VTAK) has announced the successful launch of its LockeT suture retention device in Switzerland, marking a significant expansion in its European market presence. The first clinical cases at Spitalzentrum Biel reported excellent outcomes and positive feedback from healthcare staff. The launch follows a strategic distribution agreement with FuMedica AG, designed to facilitate the deployment of LockeT across various Swiss healthcare facilities.
Read more →VTAK▼ -9.9%on this news· ran to +20% by day 3
Catheter Precision Announces Successful LockeT Launch in South Africa
Catheter Precision has successfully launched its LockeT closure device in South Africa, achieving rapid adoption across five hospitals within two months. With the collaboration of local distributor HLC Medical, hospitals are incorporating LockeT into their routine procedures. The product's features are beneficial in improving workflow and expediting patient care, fulfilling a need in emerging markets. All hospitals that implemented LockeT have placed reorders, indicating strong initial demand.
Read more →VTAKCatheter Precision Announces Third VIVO Installation in France
Catheter Precision, Inc. (VTAK) has announced the installation of its third VIVO™ system in France at the CHRU Nancy hospital. This installation is part of a multi-year agreement that aims to enhance the hospital’s capabilities in ventricular arrhythmia ablation. The VIVO system will utilize non-invasive 3D mapping technology, which is expected to streamline procedures and improve patient outcomes. The company has experienced growth globally with earlier installations in France, Sweden, and the U.S.
Read more →VTAK▼ -10.9%on this news· ran to -23% by day 3shared move
Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations
Catheter Precision, Inc. has reported significant revenue growth for both the third quarter and the first nine months of 2025. The company generated $226,000 in revenue for Q3 2025, reflecting a 135% increase over the same period last year. Despite this growth, Catheter Precision posted a GAAP net loss of $2,251,000, although this was a 45% reduction compared to the $4,120,000 loss reported in Q3 2024. The company is experiencing increasing sales activity for both its LockeT and VIVO products in several international markets following the acquisition of CE Mark approval. CEO David Jenkins expressed optimism regarding future growth fueled by clinical studies and an expanding product pipeline.
Read more →VTAKCatheter Precision Enters Distribution Agreement with FuMedica AG to Bring LockeT to Switzerland
Catheter Precision, Inc. has entered into a distribution agreement with FuMedica AG to introduce its LockeT suture retention device to Switzerland. LockeT, aimed at enhancing closure after vascular access in cardiac procedures, has been well-received globally. This collaboration is a key milestone in Catheter Precision's European growth strategy, leveraging FuMedica's strong presence in the Swiss healthcare sector. The agreement underscores the company's commitment to innovation and global expansion in cardiac care.
Read more →VTAKCatheter Precision, Inc. Announces Two New Patents to be Issued by USPTO
Catheter Precision, Inc. announced that it will receive two new patents from the USPTO. One patent focuses on methods for localizing ventricular arrhythmia using a 3D model, while the other pertains to neurostimulation devices aimed at improving cardiac function in heart failure patients. These patents underscore the company's commitment to innovation in the cardiac electrophysiology market. CEO David Jenkins highlighted that these developments enhance the company's intellectual property and market competitiveness.
Read more →VTAKCatheter Precision Announces Tender Win and First Purchase Order in Croatia
Catheter Precision, Inc. (VTAK) has announced a significant achievement by winning a tender bid and receiving a first purchase order from Dubrava University Hospital in Croatia. The hospital's Head of Electrophysiology Lab praised the VIVO system for its accuracy and efficiency in managing ventricular arrhythmias. This milestone represents a strategic expansion for the company in the European market, showcasing the value of its innovative technologies in enhancing patient care. The VIVO system has already received regulatory approvals from the U.S. FDA and the CE Mark.
Read more →VTAKCatheter Precision Announces September 10th, 2025 Record Date for October 10th, 2025 Special Meeting of Stockholders
Catheter Precision, Inc. (Ticker: VTAK) has announced a record date of September 10, 2025, ahead of its special meeting of stockholders scheduled for October 10, 2025. The meeting aims to seek stockholder approval for amendments to the company’s Certificate of Incorporation to increase authorized shares and to appoint WithumSmith+Brown, PC as the independent auditor for fiscal year 2026. A preliminary proxy statement detailing these matters is expected to be filed with the SEC on September 4, 2025.
Read more →VTAKCatheter Precision Announces Introduction of the LockeT Product Line into Italy
Catheter Precision, Inc. (VTAK) has announced the launch of its LockeT product line in Italy following a successful evaluation and initial procedures at ASST Valle Olona Hospital. This milestone is marked by the first purchase order from distributor Precise Srl, highlighting the product's acceptance in the market. The CEO expressed optimism about rapid uptake and the product's potential benefits for healthcare settings. LockeT is designed to aid in wound closure after venous punctures and holds FDA registration and CE Mark approval.
Read more →VTAK▲ +5.3%on this newsshared move
Catheter Precision Announces First Procedures in France as LockeT Expansion Continues
Catheter Precision, Inc. has successfully completed the first procedures for its LockeT device in France, marking a significant step in the product's European rollout. Conducted at CHU Rennes, these procedures indicate promising adoption rates for the company's innovative cardiac electrophysiology solutions. The LockeT device, designed to improve wound closure after venous punctures post-cardiac ablation, has already received CE Mark approval. The company anticipates continued collaboration with CHU Rennes to expand its market presence across Europe.
Read more →VTAKCatheter Precision Receives Notification of New Patent Issuance for VIVO Product Line
Catheter Precision, Inc. (VTAK) announced the issuance of a new patent for its VIVO product line, which focuses on methods of ventricular arrhythmia localization using a 3D heart model. This latest patent adds to Catheter Precision's growing intellectual property portfolio, enhancing the functionality of their non-invasive 3D imaging system designed to streamline cardiac arrhythmia procedures. CEO David Jenkins emphasized the importance of patents for their business and the potential benefits of the VIVO system for physicians in identifying arrhythmias before procedures.
Read more →VTAKCatheter Precision Announces the Start of Enrollment for the LockeT Compare Study
Catheter Precision, Inc. has commenced the LockeT Compare Study with the enrollment of its first three patients. This study aims to evaluate the safety of the LockeT suture retention device in comparison to internal closure devices after cardiac catheter procedures. Initial data suggests that LockeT is both safe and effective, potentially reducing groin complications and procedural costs. The study will ultimately involve up to 100 patients and seeks to enhance patient safety in cardiac procedures.
Read more →VTAK▲ +62.8%on this newsshared move
Catheter Precision Receives Approval for LockeT in the United Kingdom
Catheter Precision has received approval for its LockeT suture retention device in the UK, following its CE Mark certification in May 2025. This marks a crucial step in launching sales of LockeT, which supports efficient cardiac procedure recoveries and aims to alleviate NHS waiting lists. The company has partnered with HC21 for distribution, allowing for enhanced market access. LockeT’s innovative design is expected to significantly improve patient outcomes and healthcare operational efficiency.
Read more →VTAK▼ -10.7%on this news· ran to +45% by day 1shared move
Catheter Precision, Inc. Announces Effectiveness of 1-for-19 Reverse Stock Split
Catheter Precision, Inc. announced the effectiveness of its 1-for-19 reverse stock split which became active on August 15, 2025. This move is designed to consolidate shares, reducing the total issued shares from over 23 million to approximately 1.65 million. The company will continue to trade under the ticker VTAK on the NYSE American. While this consolidation might enhance share value metrics, potential risks regarding liquidity and operational challenges persist.
Read more →VTAK▼ -6.9%on this news· ran to -19% by day 3
Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025
Catheter Precision, Inc. (VTAK) reported strong operational results for Q2 2025, highlighting a 128% year-over-year increase in product sales. The company received the CE Mark for its LockeT product, enabling European sales, while also presenting compelling clinical data for its VIVO technology at the Heart Rhythm Society symposium. However, the company continues to face challenges, including a net loss of approximately $5.4 million and uncertainties regarding future financing and internal control effectiveness.
Read more →VTAK▼ -5.5%on this news
Catheters Market Size to Hit USD 95.56 Billion by 2032, Driven by a Surge in Chronic Disease Burden and Minimally Invasive Procedures | Coherent Market Insights
The global catheters market is set to grow significantly, reaching an estimated value of USD 95.56 billion by 2032, driven by increased prevalence of chronic diseases and demand for minimally invasive surgeries. Advances in technology are also enhancing catheter effectiveness and safety. However, concerns over catheter-associated infections present challenges, potentially impacting market adoption rates in healthcare settings. The growing geriatric population and rise in home-based healthcare further contribute to this growing market sector.
Read more →VTAKCatheter Precision, Inc. Announces First Purchase Order From University Hospital in Rennes, France
Catheter Precision, Inc. (VTAK) announced it has received its first purchase order from the Centre Hospitalier Universitaire (CHU) de Rennes in France, significantly marking a milestone for the VIVO product line. This purchase order is noted as the largest to date and reflects the hospital's recognition of the VIVO system’s capabilities. CHU Rennes is one of the largest ventricular ablation centers in Europe, aligning with Catheter Precision's strategy to enhance product adoption among new physicians. The VIVO system, which has received both FDA marketing clearance and CE marking, is designed to improve workflow and reduce procedure times for ventricular arrhythmias.
Read more →VTAKCatheter Precision, Inc. Forms new Joint Venture Called Kardionav to Exploit patented AI Techniques to Create New VT Software platform
Catheter Precision, Inc. has announced the formation of a joint venture called Kardionav, in collaboration with Chelak iECG, Inc., aimed at enhancing ventricular tachycardia (VT) treatment through advanced AI technology. The new venture will focus on developing a standalone ventricular mapping system to improve patient outcomes and reduce treatment times. With Dr. Jie Cheng leading the charge as the primary researcher, the partnership combines significant intellectual property and resources from both companies. Despite the potential benefits, there are ongoing concerns about the effectiveness of existing ablation techniques that the new platform intends to address.
Read more →VTAK▼ -28.3%on this news· ran to -45% by day 3
Catheter Precision (VTAK) Reports Key Progress for the LockeT Product
Catheter Precision, Inc. (VTAK) announced significant progress in the sales of its LockeT product, with Q2 2025 sales projected to be the highest to date and have already shown a 200% increase compared to the same quarter in 2024. Several prominent US hospitals are expected to make substantial purchase orders for LockeT by the end of 2025. Additionally, the company has received CE Mark approval for sales in Europe and is actively seeking more distributors across various European countries. A demonstration of LockeT is also scheduled at an upcoming symposium, aiming to boost its market visibility.
Read more →VTAK▼ -28.3%on this news· ran to -45% by day 3
Catheter Precision, Inc. Comments on Recent Market Activity
Catheter Precision, Inc. (VTAK) has issued a press release addressing recent trading activity in its shares, noting it does not have information that would typically explain this surge. The company continues to focus on its strategic plans and efforts to secure necessary financing for liquidity. No major developments have been cited, leaving the reasons for the trading activity unclear.
Read more →VTAK▲ +6.1%on this news· ran to +103% by day 3shared move
Catheter Precision, Inc. Secures VIVO Purchase Order From Sahlgrenska University Hospital
Catheter Precision, Inc. has secured its first purchase order for the VIVO product from Sahlgrenska University Hospital in Sweden. This hospital, the largest in the country, conducts a significant number of ventricular ablation procedures, providing a promising market for Catheter Precision’s technology. The CEO expressed excitement about the partnership, highlighting opportunities for training new physicians with the VIVO system. This non-invasive imaging technology has received FDA marketing clearance and CE Mark, potentially benefiting patient workflows and outcomes.
Read more →VTAK▼ -11.9%on this news
Catheter Precision, Inc. Receives CE Mark for LockeT
Catheter Precision, Inc. has received CE Mark approval for its vascular closure device, LockeT, allowing it to enter European markets. The approval is expected to significantly expand sales opportunities, with the company already receiving its first order. The device is designed for ease of use and economic advantages in cardiac procedures.
Read more →VTAKCatheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results
Catheter Precision, Inc. has released its financial results for the first quarter of 2025, showcasing a significant sales growth of 74% year-over-year. The company is expanding its product pipeline through the acquisition of Cardionomics and has received a patent allowance for the LockeT device. During the Heart Rhythm Society Symposia, promising clinical data on both LockeT and VIVO was presented, demonstrating improved patient outcomes. Despite these advancements, the company reported a net loss of approximately $4 million and has a low cash position.
Read more →VTAKCatheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic Alliance
Catheter Precision, Inc. has announced a successful $1.5 million private placement equity financing, aiming to improve its financial resources and explore strategic partnerships, particularly with QHSLab, Inc. The CEO highlighted the potential to enhance the company's reach into general cardiology while building upon their existing cardiac electrophysiology product lines. However, the company faces challenges, including the default status of QHSLab's acquired notes, which may impact their overall financial stability and future operations.
Read more →VTAKCatheter Precision, Inc. Completes Acquisition of Cardionomic Heart Failure Assets
Catheter Precision, Inc. has completed the acquisition of heart failure-related assets from Cardionomic, Inc., aiming to enhance treatment options for acute decompensated heart failure (ADHF). The acquired CPNS System utilizes electrical stimulation to address heart failure's root causes, and initial studies indicate positive outcomes. The acquisition represents a significant step forward for Catheter Precision as it expands its product offerings in the cardiac electrophysiology market. However, the company faces several challenges, including the lengthy FDA approval process and competition from existing therapies.
Read more →VTAK▼ -11%on this news
Catheter Precision to Attend and Participate in the 46th Heart Rhythm Society
Catheter Precision, Inc. (VTAK) announced its participation in the 46th Heart Rhythm Society meeting in San Diego from April 24-27, 2025. The event will feature four abstracts highlighting their products, including VIVO and LockeT, showcasing advancements such as a 94% accuracy rate for VIVO in procedural outcomes and the efficacy of LockeT in large-bore access procedures. This meeting, gathering nearly 10,000 professionals, aims to present the latest research and innovations in the field of cardiac electrophysiology.
Read more →VTAKCatheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart Failure
Catheter Precision, Inc. (VTAK) announced the acquisition of assets for the Cardiac Pulmonary Nerve Stimulation (CPNS) System, aimed at treating acute decompensated heart failure (ADHF). Initial studies showed promising clinical efficacy, with significant improvements in patient outcomes. The transaction is subject to closing conditions and has implications for future financing and FDA approval. Positive projections indicate a potential for over $1 billion in annual revenues due to the high rate of hospitalizations for heart failure in the U.S.
Read more →VTAKCatheter Precision Makes NYSE American Section 610(b) Public Announcement
Catheter Precision, Inc. (VTAK) announced that its recent audit report included a going concern opinion, indicating doubts about its financial stability. This disclosure was made in compliance with NYSE American Company Guide Section 610(b) after the release of its annual report for 2024. The announcement does not alter the company's financial statements but highlights ongoing concerns regarding its fiscal health.
Read more →VTAKCatheter Precision, Inc. Receives Notice of First Patent Allowance in the US for LockeT Product Line
Catheter Precision, Inc. has announced the receipt of its first US patent allowance for the LockeT product line, which is designed for surgical closure of orthoscopic entry wounds. The company is optimistic about market potential, particularly as it plans to start distribution in China and Europe, bolstered by existing international patents. Additionally, they anticipate receiving a CE mark for LockeT, targeting revenue generation in European markets. The device, a Class 1 FDA-registered suture retention tool, has gathered positive feedback since its US rollout.
Read more →VTAK▼ -6.3%on this news
Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results
Catheter Precision, Inc. reported its financial results for Q4 and the full year 2024, highlighting operational progress and new leadership. The company saw sequential growth in sales of its LockeT product and anticipates receiving CE Mark approval in Q2 2025, which would enable European sales. However, they also reported significant net losses and raised concerns about future liquidity and the uncertainties surrounding clinical trials.
Read more →VTAKCatheter Precision to Participate in and Share Data at Upcoming Industry Conferences
Catheter Precision, Inc. (VTAK) is set to participate in three major industry conferences in March and April 2025. The company will showcase its LockeT device at the American College of Cardiology (ACC) and its VIVO imaging system at the European Heart Rhythm Association (EHRA) and Society of Interventional Radiology (SIR) conferences. Recent clinical data suggests that LockeT outperforms traditional manual compression techniques. CEO David Jenkins emphasized the importance of attending these events for fostering collaboration and market expansion.
Read more →VTAKCatheter Precision to Attend and Participate in the Western Atrial Fibrillation Symposium
Catheter Precision, Inc. (VTAK) announced its attendance at the 18th Western Atrial Fibrillation Symposium, taking place from February 27 to March 1 in Salt Lake City, Utah. The symposium focuses on advancing atrial fibrillation (AF) diagnosis and treatment, featuring discussions led by renowned experts. CEO David Jenkins highlighted that participation aligns with their commercialization strategy and hopes to promote their LockeT suture retention device, which aids in hemostasis post-cardiac procedures. However, the company also issued caution regarding uncertainties in forward-looking statements about the product's acceptance and evaluation in hospitals.
Read more →VTAKCatheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy
Catheter Precision Inc. has partnered with PCG Advisory to enhance its investor relations strategy. The collaboration aims to improve communication with both institutional and retail investors while promoting its innovative technologies, LockeT and VIVO. CEO David Jenkins expressed optimism about the potential of these devices to improve procedural efficiency and patient care as the company enters a commercial phase.
Read more →VTAKCatheter Precision to Attend and Participate in the 13th Internation Symposium on Left Atrial Appendage
Catheter Precision, Inc. (VTAK) is set to attend the 13th International Symposium on Left Atrial Appendage (ISLAA) on February 7-8, 2025, in Austin, Texas. This symposium focuses on advancements in cardiac electrophysiology and will feature esteemed professionals from multiple renowned institutions. Catheter Precision will demonstrate its LockeT device, aimed at improving wound closure after electrophysiology procedures, potentially showcasing its practicality and effectiveness to a specialized audience. The company emphasizes the educational opportunities for fellows and aims to enhance its product's visibility in the market.
Read more →VTAKCatheter Precision, Inc. Announces The Closing of its Acquisition of PeriKard, LLC
Catheter Precision, Inc. has completed its acquisition of PeriKard, LLC, as announced on February 4, 2025. The all-stock transaction aligns with Catheter's focus on the ventricular therapeutic market. CEO David Jenkins highlighted anticipation for growth in this segment thanks to the innovative technology acquired. However, the company must navigate potential regulatory hurdles and financial challenges moving forward.
Read more →VTAK▲ +10.5%on this news
Catheter Precision, Inc. Announces Third Quarter Update and Financial Results Fort Mill, SC
Catheter Precision, Inc. provided an operational and financial update for Q3 2024, highlighting the onboarding of new leadership and an expanding pipeline with multiple hospitals engaging its products. The company anticipates a successful completion of CE Mark for its LockeT device, expected to launch in the EU by mid-2025. The financial results show a net loss impacted by commercial activities, yet the firm remains optimistic about its future growth and ongoing clinical studies that aim to validate the effectiveness of its devices.
Read more →VTAK▼ -29.2%on this news· ran to -42% by day 3
Catheter Precision, Inc. Announces Exercise of Warrants for $4.9 Million of Gross Proceeds Fort Mill, SC
Catheter Precision, Inc. has announced the exercise of warrants resulting in gross proceeds of approximately $4.9 million. This includes $3.7 million from the immediate exercise of Series E, F, G, H, and I warrants, along with an additional $1.185 million received last week. To incentivize this move, the company will issue new Series K warrants, which will have a term of 5.5 years post shareholder approval. The issuance relates to an exemption under the Securities Act, which affects share liquidity.
Read more →VTAK▼ -7.1%on this news
Catheter Introducer Sheaths Market Size on Track to Expand at 6.1% CAGR, Reaching USD 1.7 Billion by 2031| States Transparency Market Research, Inc.
The global catheter introducer sheaths market is projected to grow from USD 1.0 billion in 2022 to USD 1.7 billion by 2031, with a CAGR of 6.1%. This growth is driven by rising cardiovascular diseases, the aging population, and the shift towards minimally invasive procedures. Technological advancements in device design are enhancing procedural safety and patient comfort. Additionally, a robust healthcare infrastructure in regions like Europe supports this market expansion.
Read more →VTAK▼ -56.5%on this news· ran to -67% by day 3
Catheter Precision, Inc. Announces Pricing of $3.1 Million Underwritten Public Offering FORT MILL, SC / ACCESSWIRE /
Catheter Precision, Inc. has announced the pricing of an underwritten public offering expected to generate approximately $3.1 million in gross proceeds. The offering includes 347,277 common stock units and 2,773,000 pre-funded warrant units, with each unit priced under $1. The company has also granted underwriters a 45-day option to purchase additional shares. Closing of the offering is anticipated on or about September 3, 2024, subject to customary closing conditions.
Read more →VTAKCatheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report. Fort Mill, SC
Catheter Precision, Inc. (NYSE American: VTAK) has reported its Q2 2024 financial highlights, indicating first commercial sales of its LockeT device in the U.S. The company has made significant operational strides, including hiring 14 new sales and clinical staff and commencing product evaluations across more hospitals than projected. Despite these advancements, financial results show a net loss, and concerns about cash flow and internal controls were highlighted. The company's VIVO product is gaining traction with evaluations starting in Italy and is set to be showcased at an upcoming conference.
Read more →VTAK▼ -8.2%on this news· ran to -26% by day 3
Catheter Related Bloodstream Infection Market Size to Reach USD 2.52 Bn by 2033
The catheter-related bloodstream infection market is projected to grow from USD 1.53 billion in 2023 to approximately USD 2.52 billion by 2033, according to a report from Towards Healthcare. North America remains the dominant region, while Asia Pacific is expected to see the fastest growth. The market faces challenges from antimicrobial resistance, making treatment difficult, but advancements such as AI monitoring tools present new opportunities for infection management. Recent product innovations, including the FDA-approved DefenCath, contribute to market developments.
Read more →VTAK▼ -35%on this news
Catheter Precision, Inc. (NYSE American: VTAK) Reports Preliminary Unaudited Revenue for the Second Quarter and Six Months Ended
Catheter Precision, Inc. reported preliminary unaudited revenue figures for the second quarter and six months ending June 30, 2024. The company achieved initial sales of its LockeT device, resulting in total quarterly revenue of $94,840. This reflects a 15% increase in revenue quarter-over-quarter. The firm remains optimistic about future growth, aided by a new sales team and a promising customer pipeline, though it acknowledges several risks that could hinder its performance moving forward.
Read more →VTAKCatheter Precision, Inc. (NYSE American: VTAK) Reports Q1 2024 Highlights and Operational Performance Report. Fort Mill, SC
Catheter Precision, Inc. (NYSE: VTAK) reported its Q1 2024 financials, highlighting significant operational advancements in cardiac electrophysiology. The company submitted its LockeT device for CE Mark approval, anticipated in Q3 2024, while showcasing positive interim clinical study data. The VIVO product has successfully been utilized in several prominent European hospitals. However, the company reported a net loss of $2.7 million and has indicated a need for further financing to support its operational objectives.
Read more →VTAKCatheter Precision, Inc. (NYSE American: VTAK) Releases Operational Performance Report, Q4 and Annual 2023 Financials for Year Ending
Catheter Precision, Inc. (VTAK) has released its operational performance report and financial results for the fourth quarter and the full year of 2023. The company reported significant revenue growth, with total revenues reaching $442,000 for the year, compared to $14,000 in 2022. However, the company faced a substantial net loss of $70.6 million, primarily due to a one-time write-off of goodwill. CEO David Jenkins emphasized the company's strategic progress and product development in the cardiac electrophysiology sector, including the successful completion of clinical trials for their VIVO and LockeT products.
Read more →VTAKCATHETER PRECISION, INC. (VTAK) Reports Unaudited Preliminary Fourth Quarter and Full Year 2023 Results Fort Mill, SC
Catheter Precision, Inc. (VTAK) reported its unaudited preliminary results for the fourth quarter and year ended December 31, 2023. Total revenues reached approximately $129,000 for the quarter and approximately $442,000 for the entire year, while the net loss was significant at approximately ($72.4) million. The company highlighted several achievements, including the launch of the LockeT product and IRB approval for a Phase II study. Despite these positive developments, the substantial net loss reflects deep operational challenges.
Read more →VTAKCATHETER PRECISION, INC. Reports Third Quarter Results of Operations and Filing of Third Quarter 10-Q Fort Mill, SC
Catheter Precision, Inc. (VTAK) reported its third quarter results for 2023, highlighting key accomplishments including market expansion and advancements in clinical trials. The company received approval for its first product purchase in France and completed Phase I enrollment for its LockeT study. Despite a low revenue figure of $314 thousand and a significant net loss of $1,927 thousand, management asserts confidence due to recent progress and positive reception of their products in new hospital centers. The company aims to enhance its manufacturing processes and expects future product evaluations and purchases to grow its market presence.
Read more →VTAKCATHETER PRECISION, INC. Reports Second Quarter Results of Operations Fort Mill, SC
Catheter Precision, Inc. has reported its second quarter results for 2023, highlighting the formation of a US sales team, the onboarding of clinical personnel, and the completion of patient enrollment for their VIVO registry. The company initiated the LockeT study aimed at evaluating its product's efficacy in a clinical setting. Despite strong initial market feedback for its technologies, the company faces significant operating losses and must navigate the complexities of FDA regulations and market competition. Moving forward, Catheter Precision is focusing on strategic partnerships and product development to enhance its position in the cardiac electrophysiology market.
Read more →VTAK▼ -10.7%on this news
Catheter Precision Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q Fort Mill, SC
Catheter Precision, Inc. (VTAK) has received a notice from NYSE American regarding its non-compliance with listing standards due to a late filing of its Quarterly Report on Form 10-Q for Q2 2023. The delay is primarily attributed to the complexities surrounding the acquisition of the former Catheter Precision and a change in auditors. The company has until February 21, 2024, to rectify this situation; however, failure to file on time may result in potential suspension and delisting from the exchange. Management is currently working diligently with auditors to complete the report as soon as possible.
Read more →VTAKCatheter Introducer Sheaths Market by Qualitative Analysis [2023-2029] | by Proficient Market Insights
The report offers an extensive overview of the Catheter Introducer Sheaths market from 2023 to 2029, highlighting trends, growth potential, and competitive dynamics. It includes regional analyses focusing on major markets worldwide, such as the United States, Europe, and Asia-Pacific. The document also profiles leading companies, covering their market share and product offerings. Key market drivers, restraints, and opportunities are analyzed, with implications of recent global events like COVID-19 and the Russia-Ukraine War considered in the market forecasts.
Read more →VTAKRa Medical Systems Announces First Quarter Results Fort Mill, SC
Ra Medical Systems announced its first quarter results, revealing a net loss of $66.4 million alongside an acquisition of Catheter Precision, aimed at enhancing its cardiac electrophysiology product line. Despite closing $8 million in financing and reporting revenue of $85,000 from the new VIVO product, the company's finances were affected by substantial operational costs and an impairment related to goodwill. The financial results reflect a shift in focus after merging with Catheter, resulting in increased expenses tied to the merger process.
Read more →VTAKRa Medical Systems Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q Fort Mill, SC
Ra Medical Systems has received a notice from the NYSE American for not complying with its timely filing standards after failing to submit its Form 10-Q for the quarter ended March 31, 2023. The delay is attributed to complications in auditing the acquisition of Catheter Precision. The company has six months to rectify this issue, during which it will continue trading with an indicator of a late filer. If compliance is not achieved, there may be risks of suspension or delisting.
Read more →VTAKRa Medical Systems Announces Delayed 10-Q Filing Fort Mill, SC
Ra Medical Systems, Inc. has announced a delay in filing its Quarterly Report for Q1 2023 due to the ongoing auditor's review process. This review is particularly focused on the acquisition of Catheter Precision, with concerns about the valuation of preferred stock and related assets acquired. The company projects revenues of approximately $85,000 for the quarter, but anticipates that most of its goodwill may be written off as a result of the acquisition adjustment. No specific date for when the filing will be completed has been provided, adding to the uncertainty surrounding the company's financial situation.
Read more →VTAKRa Medical Systems Provides First Corporate Update Since Merger Sales and Clinical Field Force Onboarded and Fully Trained First Quarter Results to be Announced on
Ra Medical Systems provided its first corporate update following its merger with Catheter Precision. The company has decided to close its laser catheter business and focus resources on Catheter Precision’s cardiac electrophysiology products, including the newly launched LockeT and the VIVO system. Significant organizational changes have occurred, including layoffs and the establishment of a new CFO to improve financial management. The company successfully secured new funding and plans to announce its first quarter results on May 22, 2023.
Read more →VTAKRa Medical Announces Resignation of CEO Board Committee Seeking Replacement Fort Mill, SC
Ra Medical Systems, Inc. announced the resignation of its CEO, Will McGuire, effective April 28, 2023, citing personal reasons. Alongside his resignation, McGuire also resigns from the board of directors. The company expressed gratitude for McGuire's service and contributions. In the interim, David Jenkins, the Executive Chairman, will assume the role of CEO while a search committee seeks a full-time replacement.
Read more →VTAKCATHETER PRECISION
Catheter Precision, Inc. published its financial statements for the years ended December 31, 2022, and 2021, which indicate a fair depiction of the company's financial standing. Notably, current assets and net sales have both increased compared to the previous year, indicating some growth momentum. However, the company also reported a higher net loss and increased liabilities, highlighting ongoing financial challenges. The results underscore the need for addressable strategies to improve financial performance going forward.
Read more →VTAKCATHETER PRECISION INC.'S Management's Discussion and Analysis of Financial Condition and Results of Operations Comparison of the Twelve Months Ended
Catheter Precision Inc. reported a remarkable increase in revenue, with sales climbing from $148,569 in 2021 to $341,470 in 2022, driven by the successful market launch of their VIVO System. Gross profit also saw significant growth, indicating robust operational performance. However, the company faced rising general and administrative expenses tied to a pending merger, alongside substantial legal and professional costs. The introduction of the LockeT surgical closure device, which is anticipated to start clinical studies in Q2 2023, presents new opportunities for the company.
Read more →VTAKRa Medical Systems Completes Merger with Catheter Precision Medtech Veteran and Catheter Precision CEO and Founder David Jenkins to Serve as Executive Chairman Enters Agreements to Raise up to $9.3 Million in Equity MT.
Ra Medical Systems has completed its stock-for-stock merger with Catheter Precision, now bringing in David Jenkins as Executive Chairman. This merger allows Ra Medical to access additional capital for growth in the cardiac electrophysiology market. Catheter Precision's leading product, VIVO, is already FDA-cleared and has been used in over 800 procedures, and preparations are underway for a full commercial launch in early 2023. The combined company is also planning a private placement for approximately $9.3 million to support its operations and development strategies.
Read more →VTAKRa Medical Systems Regains Compliance with NYSE American Continued Listing Standards CARLSBAD, Calif. (
Ra Medical Systems Regains Compliance with NYSE American Continued Listing Standards CARLSBAD, Calif. (December 14, 2022) -Ra Medical Systems, Inc. (NYSE American: RMED) ("Ra Medical" or the "Company") announces that it has received notification from the NYSE American LLC ("NYSE
Read more →VTAKto the Company's Current Report on Form 8-K filed on
Catheter Precision's VIVO System Used in More Than 800 Procedures in Leading U.S. and European Hospitals MT. OLIVE, N.J. and CARLSBAD, Calif. (December 1, 2022) - Catheter Precision, Inc., a medical device and technology company focused on cardiac electrophysiology, announces th
Read more →VTAKRa Medical Systems Reports Third Quarter 2022 Financial Results CARLSBAD, Calif. (
Ra Medical Systems Reports Third Quarter 2022 Financial Results CARLSBAD, Calif. (November 14, 2022) - Ra Medical Systems, Inc. (NYSE American: RMED) ("Ra Medical" or the "Company") reports financial results for the three and nine months ended September 30, 2022 and provides a b
Read more →VTAKCatheter Precision Expands U.S. Customer Base for VIVO for Non-invasive Arrythmia Location Detection Before Ventricular Ablation Procedures MT. OLIVE, N.J. and CARLSBAD, Calif. (
Catheter Precision Expands U.S. Customer Base for VIVO for Non-invasive Arrythmia Location Detection Before Ventricular Ablation Procedures MT. OLIVE, N.J. and CARLSBAD, Calif. (October 20, 2022) - Catheter Precision, Inc. ("Catheter Precision"), a medical device company focused
Read more →VTAKRa Medical Systems Raises $7.6 Million Through Completed At-The-Market Facility CARLSBAD, Calif. (
Ra Medical Systems Raises $7.6 Million Through Completed At-The-Market Facility CARLSBAD, Calif. (October 17, 2022) -Ra Medical Systems, Inc. (NYSE American: RMED) ("Ra Medical" or the "Company") announces the completion of its at-the-market (ATM) facility, raising gross proceed
Read more →VTAKCatheter Precision Files a Method-of-Use U.S. Patent Application for its VIVO Technology MT. OLIVE, N.J. and CARLSBAD, Calif. (
Catheter Precision Files a Method-of-Use U.S. Patent Application for its VIVO Technology MT. OLIVE, N.J. and CARLSBAD, Calif. (October 4, 2022) - Catheter Precision, Inc. ("Catheter Precision"), a medical device company focused on cardiac electrophysiology, announces the filing
Read more →VTAKCatheter Precision's VIVO Technology to be Featured in Three Presentations at the Global Society of Cardiac Robotic Navigation Annual Meeting MT. OLIVE, N.J. and CARLSBAD, Calif. (
Catheter Precision's VIVO Technology to be Featured in Three Presentations at the Global Society of Cardiac Robotic Navigation Annual Meeting MT. OLIVE, N.J. and CARLSBAD, Calif. (September 29, 2022) - Catheter Precision, Inc., a medical device and technology company focused on
Read more →VTAKCatheter Precision Names Fatih Ayoglu as Business Development Manager-EMEA MT. OLIVE, N.J. and CARLSBAD, Calif. (
Catheter Precision Names Fatih Ayoglu as Business Development Manager-EMEA MT. OLIVE, N.J. and CARLSBAD, Calif. (September 27, 2022) - Catheter Precision, Inc., a medical device and technology company focused on cardiac electrophysiology, announces the appointment of Fatih Ayogl
Read more →VTAKRa Medical Systems Announces Results of its Special Meeting of Stockholders and a 1-for-50 Reverse Stock Split CARLSBAD, Calif. (
Ra Medical Systems Announces Results of its Special Meeting of Stockholders and a 1-for-50 Reverse Stock Split CARLSBAD, Calif. (September 20, 2022) - Ra Medical Systems, Inc. (NYSE American: RMED) ("Ra Medical" or the "Company") announces that at its virtual Special Meeting of
Read more →VTAKRa Medical Systems Enters Into Definitive Merger Agreement with Catheter Precision Combined Company Dedicated to Developing and Delivering Novel Technologies and Solutions to Improve the Lives of Patients with Cardiac Ar
Ra Medical Systems Enters Into Definitive Merger Agreement with Catheter Precision Combined Company Dedicated to Developing and Delivering Novel Technologies and Solutions to Improve the Lives of Patients with Cardiac Arrhythmias Medtech Veteran David Jenkins to Lead Merged Co
Read more →VTAKRa Medical Systems Receives NYSE American Notice CARLSBAD, Calif. (
Ra Medical Systems Receives NYSE American Notice CARLSBAD, Calif. (September 2, 2022) - Ra Medical Systems, Inc. (NYSE American: RMED) ("Ra Medical" or the "Company) announces that on August 31, 2022, it received a notice (the "Notice") that the NYSE American LLC has determined
Read more →VTAKRa Medical Systems Reports Second Quarter 2022 Financial Results CARLSBAD, Calif. (
Ra Medical Systems Reports Second Quarter 2022 Financial Results CARLSBAD, Calif. (August 15, 2022) - Ra Medical Systems, Inc. (NYSE American: RMED) ("Ra Medical" or the "Company") reports financial results for the three and six months ended June 30, 2022 and provides a business
Read more →VTAKRa Medical Systems Enters Into Agreements to Raise $6.2 Million Through Previously Issued Warrants and Plans Strategic Merger with Catheter Precision Inc. CARLSBAD, Calif. (
Ra Medical Systems Enters Into Agreements to Raise $6.2 Million Through Previously Issued Warrants and Plans Strategic Merger with Catheter Precision Inc. CARLSBAD, Calif. (July 22, 2022) - Ra Medical Systems, Inc. (NYSE American: RMED) ("Ra Medical" or the "Company) announces a
Read more →VTAKE xhibit 99.1 Ra Medical Systems Appoints Brian D. Conn Interim Chief Financial Officer CARLSBAD, Calif. (
Ra Medical Systems Appoints Brian D. Conn Interim Chief Financial Officer CARLSBAD, Calif. (July 18, 2022) - Ra Medical Systems, Inc. (NYSE American: RMED) ("Ra Medical" or the "Company"), a medical device company focusing on developing its excimer laser system to treat vascular
Read more →VTAKRa Medical Systems Reports First Quarter 2022 Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (
Ra Medical Systems Reports First Quarter 2022 Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (May 16, 2022) - Ra Medical Systems, Inc. (NYSE American: RMED) ("Ra Medical" or "the Company"), a medical device company focusing on developi
Read more →VTAKRa Medical Systems Reports 2021 Fourth Quarter and Full Year Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (
Ra Medical Systems Reports 2021 Fourth Quarter and Full Year Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (March 23, 2022) - Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on developing its excimer
Read more →VTAKRa Medical Systems, Inc. Announces Pricing of $12.0 Million Underwritten Public Offering CARLSBAD, Calif. (
Ra Medical Systems, Inc. Announces Pricing of $12.0 Million Underwritten Public Offering CARLSBAD, Calif. (February 4, 2022) - Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on developing its excimer laser system to treat vascular diseases, tod
Read more →VTAKRa Medical Systems Reports 2021 Third Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (
Ra Medical Systems Reports 2021 Third Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (November 15, 2021) - Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on developing its excimer laser system
Read more →VTAKDisclaimer Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Ra Medical Systems,
Ra Medical Systems, Inc. Corporate Presentation August 2021 1 Exhibit 99.1 Disclaimer Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Ra
Read more →VTAKRa Medical Systems Reports 2021 Second Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (
Ra Medical Systems Reports 2021 Second Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (August 16, 2021) - Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing its excimer laser sy
Read more →VTAKRa Medical Systems Announces Sale of Pharos Dermatology Business Company focused on the large and growing peripheral artery disease (PAD) market CARLSBAD, Calif. (
Ra Medical Systems Announces Sale of Pharos Dermatology Business Company focused on the large and growing peripheral artery disease (PAD) market CARLSBAD, Calif. (August 16, 2021) - Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializ
Read more →VTAKRa Medical Systems Reports 2021 First Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (
Ra Medical Systems Reports 2021 First Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (May 11, 2021) - Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to
Read more →VTAKRa Medical Systems Reports 2020 Fourth Quarter and Full Year Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (
Ra Medical Systems Reports 2020 Fourth Quarter and Full Year Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (March 16, 2021) - Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer
Read more →VTAKRa Medical Systems Appoints Susanne L. Meline to its Board of Directors CARLSBAD, Calif. (
Ra Medical Systems Appoints Susanne L. Meline to its Board of Directors CARLSBAD, Calif. (February 4, 2021) - Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases,
Read more →VTAKRa Medical Systems Reports Progress with Extending DABRA Catheter Shelf Life, Completes Quality Improvement Plan CARLSBAD, Calif. (
Ra Medical Systems Reports Progress with Extending DABRA Catheter Shelf Life, Completes Quality Improvement Plan CARLSBAD, Calif. (January 27, 2021) - Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to tr
Read more →VTAKRa Medical Systems Announces Settlement Resolving Previously Announced United States Department of Justice and State Investigations CARLSBAD, Calif. (
Ra Medical Systems Announces Settlement Resolving Previously Announced United States Department of Justice and State Investigations CARLSBAD, Calif. (January 4, 2021) - Ra Medical Systems, Inc. (NYSE American: RMED) today announced it has entered into a settlement agreement tha
Read more →VTAKRa Medical Systems Announces Transfer of Listing to NYSE American CARLSBAD, Calif. (
Ra Medical Systems Announces Transfer of Listing to NYSE American CARLSBAD, Calif. (December 17, 2020) - Ra Medical Systems, Inc. (NYSE: RMED) , a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces th
Read more →VTAKRa Medical Systems Announces 1-for-25 Reverse Stock Split CARLSBAD, Calif. (
Ra Medical Systems Announces 1-for-25 Reverse Stock Split CARLSBAD, Calif. (November 16, 2020) - Ra Medical Systems, Inc. (NYSE: RMED) announced today that its Board of Directors has approved a 1-for-25 reverse stock split of the Company's common stock, which will be effective a
Read more →VTAKRa Medical Systems Reports 2020 Third Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (
Ra Medical Systems Reports 2020 Third Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (November 12, 2020) - Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to tre
Read more →VTAKRA MEDICAL SYSTEMS, INC. 2018 EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED ON OCTOBER 12, 2020) 1. Purposes of the Plan . The purposes of this Plan are: • to attract and retain the best available personnel for p
RA MEDICAL SYSTEMS, INC. 2018 EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED ON OCTOBER 12, 2020) 1.Purposes of the Plan. The purposes of this Plan are: The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units
Read more →VTAKrmed-ex991_6.pptx.htm Ra Medical Systems, Inc. NYSE: RMED Corporate Presentation September 2020 Disclaimer Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. Thes
Ra Medical Systems, Inc. NYSE: RMED Corporate Presentation September 2020 Disclaimer Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Ra Me
Read more →VTAKRa Medical Systems Reports 2020 Second Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (
Ra Medical Systems Reports 2020 Second Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (August 11, 2020) - Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to trea
Read more →VTAKRa Medical Systems Announces Pricing of $12.0 Million Upsized Public Offering CARLSBAD, Calif. (
Ra Medical Systems Announces Pricing of $12.0 Million Upsized Public Offering CARLSBAD, Calif. (July 30, 2020) - Ra Medical Systems, Inc. ("Ra Medical") (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the tr
Read more →VTAKRa Medical Systems Receives Continued Listing Standard Notice from the NYSE CARLSBAD, Calif. (
Ra Medical Systems Receives Continued Listing Standard Notice from the NYSE CARLSBAD, Calif. (May 22, 2020) - Ra Medical Systems, Inc. ("Ra Medical") (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treat
Read more →VTAKRa Medical Systems Announces Pricing of $10.0 Million Public Offering CARLSBAD, Calif. (
Ra Medical Systems Announces Pricing of $10.0 Million Public Offering CARLSBAD, Calif. (May 20, 2020) - Ra Medical Systems, Inc. ("Ra Medical") (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment o
Read more →VTAKRa Medical Systems Reports 2020 First Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (
Ra Medical Systems Reports 2020 First Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (May 13, 2020) - Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat va
Read more →VTAKRa Medical Systems Appoints Joan Stafslien to its Board of Directors CARLSBAD, Calif. (
Ra Medical Systems Appoints Joan Stafslien to its Board of Directors CARLSBAD, Calif. (April 29, 2020) - Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces the
Read more →VTAKRa Medical Systems Appoints Medtech Executive Will McGuire as CEO and Director CARLSBAD, Calif. (
Ra Medical Systems Appoints Medtech Executive Will McGuire as CEO and Director CARLSBAD, Calif. (March 12, 2020) - Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, ann
Read more →VTAKRa Medical Systems Reports 2019 Fourth Quarter and Full Year Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (
Ra Medical Systems Reports 2019 Fourth Quarter and Full Year Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (March 10, 2020) - Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser sy
Read more →VTAKRa Medical Systems Receives NYSE Failure to Satisfy a Continued Listing Rule Notification CARLSBAD, Calif. (
Ra Medical Systems Receives NYSE Failure to Satisfy a Continued Listing Rule Notification CARLSBAD, Calif. (December 6, 2019) - Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological
Read more →VTAKRa Medical Systems Reports Third Quarter 2019 Financial Results CARLSBAD, Calif. (
Ra Medical Systems Reports Third Quarter 2019 Financial Results CARLSBAD, Calif. (November 29, 2019) - Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financi
Read more →VTAKRa Medical Systems Announces Substantial Completion of Audit Committee Investigation CARLSBAD, Calif. (
Ra Medical Systems Announces Substantial Completion of Audit Committee Investigation CARLSBAD, Calif. (October 31, 2019) Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseas
Read more →VTAKRa Medical Systems Receives NYSE Notice Related to Delay in Form 10-Q Filing CARLSBAD, Calif. (
Ra Medical Systems Receives NYSE Notice Related to Delay in Form 10-Q Filing CARLSBAD, Calif. (August 23, 2019) - Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, toda
Read more →VTAKRa Medical Systems Reports Preliminary Second Quarter 2019 Financial Results Announces leadership transition Announces delayed second-quarter 2019 earnings release and Form 10-Q filing Provides manufacturing update and r
Ra Medical Systems Reports Preliminary Second Quarter 2019 Financial Results Announces leadership transition Announces delayed second-quarter 2019 earnings release and Form 10-Q filing Provides manufacturing update and reports cost savings initiatives Announces Audit Committe
Read more →VTAKRa Medical Systems Reports First Quarter 2019 Financial Results Submits IDE for atherectomy clinical trial with DABRA excimer laser system Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (
Ra Medical Systems Reports First Quarter 2019 Financial Results Submits IDE for atherectomy clinical trial with DABRA excimer laser system Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif. (May 13, 2019) - Ra Medical Systems, Inc. (NYSE: RMED), a medical
Read more →VTAKRa Medical Systems Reports 2018 Fourth Quarter and Full Year Financial Results Introduces new integrated commercial strategy to support physician adoption of the DABRA laser system and build long-term customer relationsh
Ra Medical Systems Reports 2018 Fourth Quarter and Full Year Financial Results Introduces new integrated commercial strategy to support physician adoption of the DABRA laser system and build long-term customer relationships Conference call begins at 4:30 pm Eastern time today
Read more →VTAKRa Medical Systems Reports Third Quarter 2018 Results -Revenue increased nearly 60% year-over-year to $2.1 million -Increased DABRA usage agreements 325% quarter-over-quarter -Announced approval for long-term revasculari
Ra Medical Systems Reports Third Quarter 2018 Results -Revenue increased nearly 60% year-over-year to $2.1 million -Increased DABRA usage agreements 325% quarter-over-quarter -Announced approval for long-term revascularization registry of DABRA system CARLSBAD, Calif., Nov. 1
Read more →VTAKRa Medical Systems Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
Ra Medical Systems Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares October 1, 2018 Ra Medical Systems, Inc. (NYSE: RMED) today announced the closing of its initial public offering of 4,485,000 shares of com
Read more →Competitive Position
How VTAK ranks across every disease it competes inCompetitive Position is a premium feature
See how VTAK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial